Passage Bio Inc.
PASG
We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$33M
▲ +29.7% YoY
Op. Margin
–
ROIC
-172.24%
▼ -10.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$33M
▲ +34.3% YoY
Op. Cash Flow (TTM)
-$33M
▲ +34.3% YoY
Net Debt
-$20M
Net Cash Position
Cash & Equiv.
$20M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PASG
Passage Bio (PASG) in two numbers
Questions about Passage Bio
Does Passage Bio (PASG) pay a dividend?
No. Passage Bio (PASG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PASG's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PASG
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.